Pulmonary Impedance in Heart Failure with Preserved Ejection Fraction

Summary of Trial:	The purpose of this protocol is to better understand the interaction between the lung vasculature and right ventricle in patients with unexplained dyspnea, exertional fatigue, and/or heart failure with preserved ejection fraction (HFpEF). In addition to right heart catheterization hemodynamic measurements at rest and during upright exercise (a cardiopulmonary stress test), we will measure pulmonary impedance using a specialized flow wire.
Principal Investigator:	Dr. David A. Kass
Study Coordinator:	Ryan J. Tedford, M.D. Email: ryan.tedford@jhmi.edu
Study Long Title:	Pulmonary Impedance in Heart Failure with Preserved Ejection Fraction
Study Short Title:	N/A
JHU IRB Number:	NA_00041836
Funding Source:	National Institutes of Health
Inclusions:	Patients 18 years or older with unexplained dyspnea, exertional fatigue, or suspected or known Heart Failure with Preserved Ejection Fraction (HFpEF) who are referred for a clinically indicated right heart catheterization and metabolic (cardiopulmonary) stress test as part of their evaluation Left ventricular ejection fraction ≥ 45% within the last twelve months on echocardiogram Pulmonary function testing (PFT’s) within the last year Prior ischemic evaluation if clinically indicated
Exclusions:	Known reason for dyspnea or symptoms Clinically significant valvular disease Severe obstructive, restrictive, or gas exchange defect on pulmonary function testing Patients unable to consent Patients unable to exercise on an upright bicycle Pregnancy Known primary pulmonary hypertension or secondary pulmonary hypertension (not thought to be from HFpEF) Active chest pain/angina, hemodynamic instability, or other contraindication to stress testing
Clinical Trial Site:	Johns Hopkins Hospital 600 North Wolfe Street, Blalock 5th F Baltimore, MD 21287-4618
Start Date:	2010
Anticipated End Date:	2012
Compensation for Participating:	None